sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- CHU de Reims
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Association between concentration of circulating sFlt1 and use of vasopressor
研究概览
简要总结
Short description of the protocol intended for the lay public. Include a brief statement of the study hypothesis (Limit : 5000 characters) The management of critically-ill patients with organ failure due to COVID-19 represents a major healthcare burden. While endothelial inflammation has been reported in these patients, the pathophysiological mechanisms remain incompletely elucidated.
详细描述
Extended description of the protocol, including more technical information (as compared to the Brief Summary) if desired. Do not include the entire protocol; do not duplicate information recorded in other data elements, such as eligibility criteria or outcome measures. (Limit : 32 000 characters)
The soluble fms-like tyrosine kinase 1 (SFlt1) is the soluble form of VEGF-A receptor 1 (VEGFR1). By linking VEGF-A with a high affinity, sFlt1 blocks the VEGF-A / VEFR1 axis and impairs endothelial homeostasis. Its production increases during inflammation. We hypothesize that sFlt1 is upregulated and correlates with endothelial dysfunction and outcomes in critically-ill patients with COVID-19.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient with documented COVID-19 (positive PCR)
- •Hospitalized in University Hospital of Reims
- •Patient or family who have previously consented
排除标准
- •Patient <18 yo
- •Patient not insured under the French social security
结局指标
主要结局
Association between concentration of circulating sFlt1 and use of vasopressor
时间窗: 14 days
次要结局
未报告次要终点